Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Emcure Ref: EPL/CS/SE/0087/2026 Date: October 02, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) – Regulatory Order(s) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby submit that with respect to the ongoing litigations disclosed by Emcure Pharmaceuticals Limited (“the Company”), in the Integrated Governance Reports filed, latest being for the quarter ended June 30, 2026, the Company has received various orders from the Income-tax Department imposing an aggregate penalty of Rs. 57,73,96,732 for Financial Year 2014-15 to Financial Year 2020-21 (Assessment Year 2015-16 to Assessment Year 2021-22), as detailed in Annexure A. The Company is in the process of evaluating appropriate legal remedies, including filing an appeal before the Appellate Authority. The relevant details as required pursuant to Regulation 30 and Para B(8) of Part A of Schedule III of Listing Regulations are provided in “Annexure A”, enclosed herewith. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary and Compliance Officer ICSI Membership No.: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Annexure-A Disclosure under Part A of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Sr. No. Particulars Information 1 Name of the opposing party Deputy Commissioner of Income tax, Central Circle 2 (1)- Pune (Income-tax Department) 2 Date of initiation of the litigation December 27, 2023 / dispute 3 Status of the litigation / dispute as As per the disclosure made in Integrated per last disclosure Governance Report filed for the quarter ended June 30, 2026. 4 Current status of the litigation / Orders received for the Financial Year 2014-15 dispute until Financial Year 2020-21 (Assessment Year 2015-16 to Assessment Year 2021-22) imposing an aggregate penalty of Rs. 57,73,96,732/- Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251